Journal of Cardiovascular Pharmacology and Therapeutics

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spirou, A.
Right arrow Articles by Elisaf, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spirou, A.
Right arrow Articles by Elisaf, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 11, No. 4, 256-261 (2006)
DOI: 10.1177/1074248406296108

Effect of Barnidipine on Blood Pressure and Serum Metabolic Parameters in Patients With Essential Hypertension: A Pilot Study

Athanasia Spirou, MD

Evangelos Rizos, MD, DSc

Evangelos N. Liberopoulos, MD, DSc, FASA, FRSH

Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Nikolaos Kolaitis, MD, PhD

Hematology Laboratory, University Hospital of Ioannina, Ioannina, Greece

Apostolos Achimastos, MD, DSc

Department of Internal Medicine, Medical School, University of Athens, Athens, Greece

Alexandros D. Tselepis, MD, PhD

Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece

Moses Elisaf, MD, DSc, FASA, FRSH

Department of Internal Medicine, Medical School, University of Ioannina, 451 10 Ioannina, Greece; egepi{at}cc.uoi.gr;vaglimp@yahoo.com

The effect of barnidipine, a calcium channel blocker, on metabolic parameters is not well known. The authors conducted the present pilot study to evaluate the possible effects of barnidipine on parameters involved in atherogenesis, oxidative stress, and clotting activity. This open-label intervention study included 40 adult patients with essential hypertension who received barnidipine 10 mg once daily. Barnidipine significantly reduced systolic and diastolic blood pressure as well as isoprostane levels, which represent a reliable marker of oxidative stress. In contrast, barnidipine had a neutral effect on lipid profile and apolipoprotein levels, did not influence glucose homeostasis, had no effect on renal function, and did not cause any changes in electrolyte levels. Moreover, barnidipine did not affect either the clotting/fibrinolytic status (evaluated by measurement of fibrinogen, total plasminogen activator inhibitor, tissue plasminogen activator, and a2 antiplasmin) or the enzymatic activity of the inflammatory/anti-inflammatory mediators lipoprotein-associated phospholipase A2 and paraoxonase 1, respectively. Barnidipine should be mainly considered as an antihypertensive agent with neutral effects on most of the studied metabolic parameters in hypertensive patients. Any antioxidant effect of barnidipine needs further investigation.

Key Words: barnidipine • hypertension • isoprostane • cholesterol • lipoprotein-associated phospholipase A2 • plasminogen activator inhibitor 1 • paraoxonase • fibrinogen • metabolic parameters

References

  • Liau CS. Barnidipine: a new calcium channel blocker for hypertension treatment. Expert Rev Cardiovasc Ther. 2005;3:207-213.[CrossRef][Medline] [Order article via Infotrieve]
  • Malhotra HS, Plosker GL. Barnidipine. Drugs. 2001; 61:989-996.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol. 2005;46:1978-1985.[Abstract/Free Full Text]
  • Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004;109(23 suppl 1):III20-III26.
  • Fruchart JC, Nierman MC, Stroes ES, et al. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109(23 suppl 1):III15-III19.
  • Romero JC, Reckelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension. 1999; 34:943-949.[Abstract/Free Full Text]
  • Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2003;284:R893-R912.[Abstract/Free Full Text]
  • Liberopoulos EN, Papavasiliou E, Miltiadous GA, et al. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int. 2004;24:580-589.[Abstract/Free Full Text]
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-2497.[Free Full Text]
  • Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.[Free Full Text]
  • Patrignani P, Tacconelli S. Isoprostanes and other markers of peroxidation in atherosclerosis. Biomarkers. 2005;10(suppl 1):S24-S29.
  • Lerman LO, Nath KA, Rodriguez-Porcel M, et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001;37:541-546.[Abstract/Free Full Text]
  • Laragh JH. Two forms of vasoconstriction in systemic hypertension. Am J Cardiol. 1987;60:82G-93G.[CrossRef][Medline] [Order article via Infotrieve]
  • Krier JD, Rodriguez-Porcel M, Best PJ, et al. Vascular responses in vivo to 8-epi PGF(2alpha) in normal and hypercholesterolemic pigs. Am J Physiol Regul Integr Comp Physiol. 2002;283:R303-R308.[Abstract/Free Full Text]
  • Ganafa AA, Walton M, Eatman D, et al. Amlodipine attenuates oxidative stress-induced hypertension. Am J Hypertens. 2004;17:743-748.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Zhou MS, Jaimes EA, Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens. 2004;17: 167-171.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemiaassociated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002;22:1208-1212.[Abstract/Free Full Text]
  • Eisaf M, Tselepis AD. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase: implication for atherosclerosis. Biochem Pharmacol. 2003;66:2069-2073.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Chait A, Han CY, Oram JF, et al. The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res. 2005;46:389-403.[Abstract/Free Full Text]
  • Rizos E, Tambaki AP, Gazi I, et al. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids. 2005;72:203-209.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Tambaki AP, Rizos E, Tsimihodimos V, et al. Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. J Cardiovasc Pharmacol Ther. 2004;9:91-95.[Abstract/Free Full Text]
  • Kosegawa I, Inaba M, Morita T, et al. Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens. 1998;20:751-761.[ISI][Medline] [Order article via Infotrieve]
  • Fogari R, Derosa G, Zoppi A, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res. 2005;28:209-214.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Derosa G, Cicero AF, Bertone G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther. 2004;26:1228-1236.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Koyama Y, Kodama K, Suzuki M, et al. Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens. 2002;15:927-931.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Dahlöf B, Sever PS, Poulter NR, et al, ASCOT Investigators. Prevention of cardiovascular events with an anti-hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366:895-906.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens. 2004;22:1453-1458.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Whelton PK, Barzilay J, Cushman WC, et al, ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005; 165:1401-1409.[Abstract/Free Full Text]
  • Liberopoulos EN, Tsouli S, Mikhailidis DP, et al. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets. 2006;7:211-228.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation. 2002;105:457-461.
  • Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005;27:578-587.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Ridderstrale W, Ulfhammer E, Jern S, et al. Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy. Hypertension. 2006;47:686-691.[Abstract/Free Full Text]
  • Salvetti A, Ghiadoni L. Guidelines for antihypertensive treatment: an update after the ALLHAT study. J Am Soc Nephrol. 2004;15(suppl 1):S51-S54.[Abstract/Free Full Text]
  • de Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med. 2004;164:2459-2464.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spirou, A.
Right arrow Articles by Elisaf, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spirou, A.
Right arrow Articles by Elisaf, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?